Welcome to our dedicated page for Aardvark Therapeutics SEC filings (Ticker: AARD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aardvark Therapeutics, Inc. (Nasdaq: AARD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Aardvark uses forms such as Form 8-K to report material events, clinical and scientific updates, and quarterly financial results related to its pipeline of small-molecule therapies for Prader-Willi Syndrome and metabolic diseases.
Recent AARD filings include Form 8-K reports furnishing quarterly financial results and business updates, such as results for periods ended June 30 and September 30, along with commentary on research and development spending, general and administrative expenses, and cash, cash equivalents, and short-term investments. These filings often incorporate press releases as exhibits, giving investors a consolidated view of the company’s financial condition and development plans.
Aardvark also files 8-Ks under Items 7.01 and 8.01 to describe clinical and scientific milestones, including presentations at ObesityWeek, new preclinical data on ARD-201 and WE-868, and alignment with the U.S. Food and Drug Administration on protocol amendments to the Phase 3 HERO trial of ARD-101 in Prader-Willi Syndrome. Other 8-Ks document investor webinars reviewing ARD-101 and ARD-201 programs and provide access to slide presentations used in those events.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on topics such as clinical trial progress, regulatory interactions, financial trends, and risk factor references. Users can monitor new 8-Ks and, when available, 10-Q and 10-K reports to follow how Aardvark describes its pipeline, capital resources, and development risks over time.
For those researching AARD stock, this filings page offers a structured way to review the company’s official disclosures, including material events, scientific data announcements, and financial reporting, with tools that make complex SEC documents easier to interpret.
Aardvark Therapeutics has voluntarily paused its Phase 3 HERO trial of ARD-101 in Prader-Willi syndrome, along with the related open-label extension. The pause follows reversible cardiac observations at above target therapeutic doses seen during routine safety monitoring in a healthy volunteer study.
The company is conducting a comprehensive data review and has temporarily halted enrollment and dosing in HERO out of caution. As a result, Aardvark no longer expects to report topline HERO data in the third quarter of 2026 and plans to give updated timing guidance in the second quarter of this year.
Aardvark Therapeutics filed a current report describing leadership changes and the creation of a new dermatology-focused subsidiary. The company formed Ardia Therapeutics, a wholly owned U.S. unit that will develop DIA-615, a clinic-ready topical candidate for inflammatory skin diseases such as psoriasis.
Former Chief Operating Officer Bryan Jones, Ph.D., became Ardia’s Chief Executive Officer and entered a letter agreement covering salary through up to nine months after his transition, continued option exercisability while employed at Ardia, and accelerated vesting of 17,797 stock options plus monthly vesting of 2,542 additional options for three months. Nelson Sun, already Chief Financial Officer, was appointed Chief Operating Officer as well, with no material compensation change, and Derrick C. Li was named Chief Business Officer. The filing reiterates Aardvark’s core pipeline, including Phase 3 oral ARD-101 for Prader-Willi syndrome and Phase 2 combination candidate ARD-201 for obesity-related conditions.
Aardvark Therapeutics, Inc. reported that Chief Financial Officer Nelson Sun received a new stock option grant. On February 9, 2026, he was granted an option to buy 70,549 shares of common stock at an exercise price of
According to the vesting terms, one quarter of these option shares vest on
Aardvark Therapeutics Chief Medical Officer receives stock option grant. Chief Medical Officer Manasi Jaiman was granted a stock option to buy 70,549 shares of Aardvark Therapeutics common stock at an exercise price of $13.48 per share on February 9, 2026.
The option vests over four years: one-quarter of the shares vest on February 9, 2027, and the remaining shares vest in equal monthly installments thereafter, subject to continued service. Following this grant, 70,549 derivative securities are beneficially owned directly.
Aardvark Therapeutics, Inc. director, chief executive officer, and 10% owner Lee Tien-Li reported receiving a stock option grant. On February 9, 2026, they were granted an option to buy 203,851 shares of common stock at an exercise price of $13.48 per share.
According to the vesting terms, one quarter of the option will vest on February 9, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, contingent on continued service. After this grant, 203,851 derivative securities are held directly.
Aardvark Therapeutics, Inc. announced U.S. Institutional Review Board approval of an amended protocol for its Phase 3 HERO trial of lead candidate ARD-101 in Prader-Willi Syndrome. The change lowers the minimum enrollment age from 10 to 7 years for U.S. participants.
The randomized, double-blind, placebo-controlled HERO study plans to enroll 90 patients across the U.S., Australia, Canada, the U.K. and South Korea, measuring change in Hyperphagia Questionnaire for Clinical Trials scores at Week 12 as the primary endpoint. Enrollment is described as progressing steadily, with topline data targeted for the third quarter of 2026.
Aardvark Therapeutics, Inc. filed a current report to note that on January 12, 2026 it updated its corporate presentation. The presentation, dated January 2026, is intended for meetings with investors, analysts and other stakeholders and will also be posted on the company’s website.
The updated corporate presentation is furnished as Exhibit 99.1 and is incorporated by reference into the Other Events section. The company states the presentation is current as of January 12, 2026 and disclaims any obligation to update this material in the future.
Aardvark Therapeutics, Inc. reported an insider share purchase by its Chief Financial Officer, Nelson Sun. On 12/11/2025, he bought 3,000 shares of common stock in an open-market transaction coded "P" at a price of $14.40 per share. After this transaction, he beneficially owns 108,484 shares of Aardvark Therapeutics common stock in direct ownership.
Aardvark Therapeutics, Inc.7,000 shares of common stock at a price of $14.485 per share. Following this transaction, the insider beneficially owned 1,551,613 common shares directly and 1,474,028 common shares indirectly through a spouse, according to the filing.
Aardvark Therapeutics (AARD) filed its Q3 2025 10‑Q, reporting a net loss of $16.3 million for the quarter and $40.0 million year‑to‑date. Operating expenses rose as the company advanced its pipeline, with Q3 research and development at $13.7 million and general and administrative at $4.0 million.
Liquidity strengthened after the February 2025 IPO, which raised approximately $87.5 million net. As of September 30, 2025, cash, cash equivalents and short‑term investments totaled $126.4 million, which management believes supports operations for at least one year after issuance and, based on current plans, into 2027. Total assets were $133.2 million and stockholders’ equity was $122.4 million.
The company is running the Phase 3 HERO trial of ARD‑101 in Prader‑Willi syndrome, initiated in December 2024 with enrollment underway since Q2 2025. In October 2025, eligibility was expanded by lowering the minimum age to 10 years. Topline HERO data are anticipated in Q3 2026. Shares outstanding were 21,745,265 as of September 30, 2025; 21,773,272 as of November 3, 2025.